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A 59-year-old man who was a current smoker (30 pack-years) was referred to the outpatient department of our
hospital for evaluation of a huge left hilar mass with bilateral
diffuse opacification of the lung fields on the chest x-ray.
Although the patient had no symptoms at his first visit to our
clinic, he soon developed progressive dyspnea of acute onset
with hypoxemia necessitating oxygen supplementation and
continuous bronchorrhea (300 mL/d). Moreover, he could
not lie on his back because of the bronchorrhea flooding out
of the nose in this position. The results of arterial blood gas
analysis on room air were as follows: pH, 7.422; PaO2, 60.3
torr; PaCO2, 35.6 torr; HCO3, 23.2 mEq/L; BE, 0.6; O2 Sat,
91.7%. Fiberoptic bronchoscopy and transbronchial lung bi-
opsy revealed the diagnosis of adenocarcinoma in specimens
obtained from the apical segment of the left lower lobe; no
malignant cells were identified in the bronchoscopic aspirates
obtained from the other lobes. Although repeat sputum cy-
tology did not reveal any malignant cells, the carcinoembry-
onic antigen level in the sputum was 128 mg/dL as compared
with that of 4.2 mg/dL in the serum. High-resolution com-
puted tomography (CT) revealed bilateral diffuse ground-
glass attenuation (GGA) of the pulmonary parenchyma, in
addition to a huge round area of consolidation in the apical
segment of the left lower lobe (Figure 1). Positron emission
tomography with fluorine-18 fluorodeoxyglucose showed a
high standardized uptake value of 7.4 in the pulmonary tumor
and regional hilar lymph nodes, with no evidence of any
metastatic disease (Figure 2). We obtained informed consent
from the patient for surgery after explaining to him that the
surgical procedure to be undertaken may not be curative, but
palliative in terms of providing relief from the disabling
symptoms of bronchorrhea and dyspnea and improving the
arterial oxygen saturation, and performed a left lower lobec-
tomy with systematic radical lymph node dissection. Al-
though a lingular segment obtained by wedge resection did
not reveal any evidence of metastasis, multiple small in-
trapulmonary metastases were evident in the resected left
lower lobe. Histopathological examination revealed adeno-
carcinoma with mucinous bronchioloalveolar adenocarci-
noma (BAC) features (Figure 3) and hilar lymph node me-
tastases; pT3N1M0, stage IIIA. Epidermal growth factor
receptor direct sequencing of exons 18 to 22 revealed the wild
type. The postoperative course was uneventful. The symp-
toms of bronchorrhea and dyspnea disappeared rapidly, and
by the end of day 2 postoperatively, the patient no longer
needed oxygen supplementation; arterial blood gas analysis at
this time showed a PaO2 of 88.1 torr on room air. A postop-
erative CT obtained 3 weeks after the surgery (Figure 4)
revealed complete disappearance of the diffuse GGA in the
residual pulmonary parenchyma. Although he has taken ad-
juvant chemotherapy with paclitaxel and carboplatin and
been well without any pulmonary symptom, a postoperative
CT obtained 4 months after surgery revealed difuuse GGA in
bilateral lungs suggesting intrapulmonary recurrence.
DISCUSSION
Mucinous BAC and adenocarcinoma of the lung may
typically present with the specific clinical features of bron-
chorrhea or hypoxemia caused by intrapulmonary dissemina-
tion of the disease due to bronchial or lymphatic spread. As
the diffuse disease associated with the mucin-producing tu-
mor is regarded as a metastatic disease, bilateral BAC is
usually considered as a contraindication to surgery.1 More-
over, it is usually reported to be resistant to platinum-based
chemotherapy and small-molecular tyrosine kinase inhibi-
tors.2,3 Few medical strategies are available for effective
palliation of the respiratory distress caused by bronchorrhea
in patients with diffuse BAC, although oral erythromycin,
tyrosine kinase inhibitors, or inhaled indomethacin have been
reported to inhibit the bronchial hypersecretion and provide
temporary relief from the symptoms in a few cases.1,4,5
We report successful treatment of a patient of mucinous
lung adenocarcinoma presenting with bronchorrhea by left
lower lobectomy. The surgery was performed as a palliative
intent for providing relief from the disabling symptoms of
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bronchorrhea and dyspnea and improving the arterial oxygen
saturation, rather than as curative resection. It was difficult to
distinguish intrapulmonary aspiration of mucus produced in
massive amounts by the tumor, manifesting as bronchorrhea,
from intrapulmonary dissemination preoperatively, because
GGA on high-resolution CT, the extensive alveolar filling pat-
tern, may represent aspiration pneumonia or the “field effect” of
the tumor or other modes of dissemination such as aerogenous
spread and lympho-vascular permeation. The findings on the
postoperative CT obtained 3 weeks after the surgery (Figure 4)
revealed complete disappearance of the diffuse GGA in the
residual pulmonary parenchyma might suggest that most of
the diffuse GGA involving multiple lung lobes observed on the
preoperative CT images was likely to have been due to bron-
chorrhea by the mucus producing tumor rather than to intrapul-
monary metastases. As the fact that the pathology demonstrated
intrapulmonary spread within the lobe worried us considerably
that the bilateral changes might end up being malignant in origin
despite the improvement on CT, a postoperative CT obtained 4
months after surgery revealed difuuse GGA in bilateral lungs
suggesting intrapulmonary recurrence of mucinous BAC or
adenocarcinoma. However, surgery could bring not only a dim-
inution of the symptoms of dyspnea, hypoxemia, and bronchor-
rhea but also a chance to take systemic chemotherapy in this
case. Although further follow-up is needed, surgical manage-
ment of patients presenting with diffuse GGA may be consid-
ered for highly selected patients, in particular, those with the
disabling symptom of intractable bronchorrhea.1
FIGURE 2. Coronal positron emission tomography (PET)
slice showing increased fluorodeoxyglucose (FDG) uptakes in
the pulmonary tumor and regional hilar lymph nodes (maxi-
mal standardized uptake value 7.4).
FIGURE 4. Postoperative CT showing complete disappear-
ance of the bilateral diffuse ground-glass attenuation follow-
ing left lower lobectomy.
FIGURE 1. Preoperative computed tomography (CT) scan
showing bilateral diffuse ground-glass attenuation and mass-
like consolidation in the apical segment of the left lower
lobe.
FIGURE 3. Microscopic findings of the primary tumor: A,
(hematoxylin and eosin [H&E] 20) Bronchioloalveolar car-
cinoma. B, (H&E 200) Mucinous tumor cells that were re-
sponsible for the massive bronchorrhea.
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